OIST Seminar



DATE: Wednesday March 5th

TIME: 15:00 – 16:00

VENUE: C210

SPEAKER: Dr. Yoichi Kurebayashi

**TITLE:　Mission of “All Japan” Drug Discovery Support Network: Promotion of Academic Drug Research**

**Speaker’s Profile**

Yoichi Kurebayashi, PhD.

Vice President of National Institute of Biomedical Innovation (NIBIO)

Director, Center for Innovative Drug Discovery and Development

Dr. Yoichi Kurebayashi has been recently appointed the vice president of the National Institute of Biomedical Innovation (NIBIO) to lead the Center for Innovative Drug Discovery and Development. Dr. Kurebayashi started his industry career at Daiichi Pharmaceutical Co. Ltd. in 1979 as a medicinal biologist, after receiving MSc. from Tokyo University of Agriculture and Technology. In 1986, he was granted PhD from The University of Tokyo. Later he served as Head of Institute of Allergy at Bayer’s Research Center Kyoto, and Vice President of Discovery Research Japan at Pfizer Global Research and Development, during which time he led multiple global project teams for drug discovery and development. In November 2007, taking advantage of the long industry experience, Dr. Kurebayashi joined Kobe University as a professor of the Center for Collaborative Research and Technology Development, and was additionally appointed as a professor of the Graduate School of Medicine to chair the division of Integrated Drug Discovery Sciences, where he was engaged in research and education for sparking university-industry partnership and technology transfer. In April 2013, he rose to the new challenge at the NIBIO to take a lead role in the Drug Discovery Support Network.

ABSTRACT:

The Center for Innovative Drug Discovery and Development (iD3) was established in May 2013 within the National Institute of Biomedical innovation (NIBIO) in Osaka as the headquarters of the Drug Discovery Support Network (DDSN). The mission of DDSN is to promote drug discovery research and to put outstanding life science research results in academia into practical use as innovative new drugs through close collaboration among multi-disciplinary academic research institutes including RIKEN, National Institute of Advanced Industrial Science and Technology (AIST) and NIBIO in advance of official establishment of Japanese NIH in 2015. In this seminar, we would like to introduce the mission of the DDSN and how it will support translation of basic research into drug discovery and development in Japan.